arrow
R

Raymone Pajarillo

University of Pennsylvania
H指数:15
被引数:1,564

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells

针对IGHV4-34 b细胞受体的嵌合抗原受体T细胞特异性消除肿瘤性和自身免疫性b细胞

2026-02-040
PRE
CD5 deletion enhances the antitumor activity of adoptive T cell therapies

CD5缺失增强过继性T细胞疗法的抗肿瘤活性

2024-07-195
PRE
Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing

制造过程中嵌合抗原受体T细胞浓度,大小,活力和双色表型的简化测量

2024-05-010
PRE
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel

苯达莫司汀用于利索卡塔烯前淋巴细胞耗竭的疗效和安全性

2024-04-220
OAAI
Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia

淋巴瘤和慢性淋巴细胞白血病患者疫苗反应性的免疫学预测指标

2024-03-042
PRE
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines

苯达莫司汀在axicabtagene ciloleucel之前进行淋巴细胞耗竭是安全的,并且与减少的炎症细胞因子有关

2024-01-268
OAAI
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

商业CAR T细胞治疗后T细胞淋巴瘤和继发性原发性恶性肿瘤风险

2024-01-2481
PRE
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

靶向CD19近膜域的新型anti-CD19嵌合抗原受体T细胞产品对非霍奇金淋巴瘤的安全性和有效性: 一项首次人体研究

2023-12-098
OAAI
Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy

调节肠道菌群参与抗原交叉呈递以增强CAR T细胞免疫疗法的抗肿瘤作用

2023-03-0120
OAAI
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy (March, 10.1038/s41591-022-01702-9, 2022)
2022-10-173
OA
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
2022-09-0147
OAAI
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer
2022-07-2944
OA
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

肠道微生物组与anti-CD19 CAR T细胞治疗后的反应和毒性相关

2022-03-14158
OA
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells
2021-04-22112
OA
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction

白血病死亡受体信号受损通过诱导CAR T细胞功能障碍导致抗原非依赖性耐药

2020-04-01206
OAAI